Table 1. Drug sensitivity of parental cell lines and cell lines with acquired erlotinib resistance.
| Cell line | Volasertib | Erlotinib | ||||
|---|---|---|---|---|---|---|
| IC50(μM) | IC70(μM) | AUC | IC50(μM) | IC70(μM) | AUC | |
| PC9 | 0.03 | 0.05 | 0.30 | 0.50 | 0.50 | 0.02 |
| PC9-ER3 | 0.06 | 0.10 | 0.54 | 2.41 | 2.93 | 0.71 |
| PC9-ER6 | 0.06 | 0.10 | 0.57 | 3.07 | 3.76 | 0.70 |
| PC9-ER8 | 0.05 | 0.08 | 0.46 | 2.28 | 4.00 | 0.59 |
| PC9-ER9 | 0.05 | 0.16 | 0.57 | 3.46 | 3.99 | 0.83 |
| PC9-ER11 | 0.05 | 0.16 | 0.51 | 2.53 | 4.00 | 0.63 |
| HCC4006 | 0.16 | 0.16 | 0.61 | 0.50 | 3.61 | 0.34 |
| HCC4006-ER2 | 0.03 | 0.04 | 0.31 | 4.00 | 4.00 | 0.69 |
| HCC827 | 0.02 | 0.16 | 0.45 | 0.50 | 0.50 | 0.08 |
| HCC827-ER3 | 0.03 | 0.03 | 0.22 | 4.00 | 4.00 | 0.95 |
Abbreviations: IC50: half maximal inhibitory concentration; IC70: 70 percent inhibitory concentration; AUC: Area Under Curve